TE Tirzepatide Editorial

Governance

Source and Citation Policy

Released: · Last reviewed:

Direct answer

Sources on this site are named, dated, and linked wherever possible. Clinical claims cite FDA labelling or a specific trial with its ClinicalTrials.gov identifier, PubMed identifier, and DOI. Commercial claims cite a dated capture of a named provider page. Citation-shaped phrases that name no source are prohibited, because they transfer confidence to a reader without transferring anything checkable.

Key takeaways

  • Clinical claims cite a specific trial with NCT, PMID, and DOI, or FDA labelling.
  • Commercial claims cite a dated capture from a named provider source.
  • Vague attributions of the studies-show or widely-reported variety are prohibited.
  • Where an identifier has not been verified, the numeric claim is withheld rather than cited loosely.
  • Outbound links carry rel="nofollow noopener" and UTM parameters and open in a new tab. Links to clinical and regulatory sources earn nothing; provider links may, as the footer disclosure states.
Key facts
Clinical sourcesFDA labelling, peer-reviewed literature, ClinicalTrials.gov
Identifier standardNCT + PMID + DOI where a trial result is asserted
Commercial sourcesDated first-party capture of a named provider page
Regulatory sourcesFDA, state boards of pharmacy
ProhibitedStudies-show, widely-reported, or experts-agree attributions without a named source
Verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-07-22
Updated
Methodology v4.1

Why require three identifiers for a trial?

Because each does a different job. The NCT number identifies the registered protocol, which reveals the design and endpoints as pre-specified. The PMID locates the peer-reviewed publication. The DOI provides a stable link to the article itself. Together they let a reader check not only what was published but whether it matches what was registered.

What counts as a citable source?

Source hierarchy applied across the site
TierSource typeUsed for
1FDA labelling and approved product informationIndications, warnings, contraindications
1Peer-reviewed primary trial publicationsEfficacy and safety results
1ClinicalTrials.gov registry recordsDesign, population, endpoints, sponsor
2State boards of pharmacy and regulatory noticesLicensure, facility status, enforcement
3Dated first-party captures of provider pagesPricing, fees, terms
—Provider marketing claims without verificationNot cited as fact
Why the widely-reported construction is banned. It is a citation-shaped phrase with no citation in it. It transfers confidence to the reader without transferring anything checkable, and it is the most common way inaccurate claims spread between health websites.

How much of this site's data is actually verified?

Trials with full identifiers8Trials partially verified1Trials withheld pending audit1Providers with a standing all-in price15Providers listed with a reason28$/month
The published state of every dataset behind this site. Of 43 provider records in the November 8, 2026 index, 15 publish a standing all-in price; the other 28 are listed with the reason (18 print a figure that is not like-for-like, 10 have no comparable price) rather than being quietly estimated.
Data for: Verification state of the published datasets
GroupRecords
Trials with full identifiers8
Trials partially verified1
Trials withheld pending audit1
Providers with a standing all-in price15
Providers listed with a reason28
Evidence statuses applied across every page and dataset
Evidence statusDefinitionWhat may be published
VerifiedChecked against a primary source with a recorded dateThe claim, with its identifier and date
Partially verifiedSome elements confirmed, others outstandingConfirmed elements only; the rest labelled
Verification PendingNot yet checked against a primary sourceNo factual assertion — the gap is shown

What does this page cover, and what does it deliberately leave out?

This page addresses FDA, labels, PubMed, ClinicalTrials.gov, boards and first-party captures, organised around the primary question of tirzepatide source policy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.

Scope of this page and the basis for each element
ElementTreatment hereEvidence basis
FdaCovered on this pageRegulatory or policy source
LabelsCovered on this pageRegulatory or policy source
PubmedCovered on this pageRegulatory or policy source
Clinicaltrials.govCovered on this pageRegulatory or policy source
BoardsCovered on this pageRegulatory or policy source
First-party capturesCovered on this pageRegulatory or policy source
Individualized clinical instructionDeliberately not coveredBelongs with the corrections process

What are the limits of what this page can tell you?

Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.

Specific limitations.
  • The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
  • Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
  • Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
  • Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.

What would change the conclusion on this page?

This page would be revised, with the change recorded in its history, if any of the following occurred:

  • New primary evidence bearing directly on tirzepatide source policy.
  • A change to FDA labelling affecting any statement made above.
  • A verified correction submitted through the corrections process and accepted on the evidence.
  • A material change to a captured record, including a price, term, or regulatory status.
  • Completion of a verification currently marked pending, which would replace a gap with a stated fact.

What do the technical terms on this page mean?

Definitions for the 5 technical terms this page uses, including DOI, NCT number, PMID, contraindication — in the specific sense used above.

Terms used on this page
DOIDigital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website.
NCT numberThe identifier assigned to a study registered on ClinicalTrials.gov. It allows a reader to check the pre-specified design and endpoints against what was eventually published.
PMIDPubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database.
contraindicationA circumstance in which a drug should not be used at all. For tirzepatide these include a personal or family history of medullary thyroid carcinoma and MEN2.
endpointThe outcome a trial is designed to measure. A primary endpoint is specified before the trial begins; secondary and exploratory endpoints carry progressively weaker inferential weight.

Frequently asked questions

What sources do you cite for clinical claims?

FDA labelling and specific trials identified by NCT, PMID, and DOI.

How are provider prices sourced?

From a dated capture of a named provider page, with the capture date shown.

Why avoid studies-show phrasing?

Because they imply a citation without providing one and cannot be checked.

Are source links monetised?

Links to clinical and regulatory sources are not. The site is affiliate-supported, so links to providers may earn a commission, as the general disclosure in the footer of every page states. All outbound links carry rel="nofollow noopener".

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.
2026-09-04Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears).
2026-11-08Statement that no outbound link is monetised corrected: the site is affiliate-supported and provider links may earn a commission; outbound links carry rel="nofollow noopener" with UTM parameters. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price).

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?